Congrates folks...Like seeing QGEN taking off. Though not a shareholder, QGEN doing well means their collaboration with Sequenom moving well. Anyone know that part of their business in Livestock and Agriculture with SQNM partnership?
liambert, as i get time i will try to share additional data with you, you may be amazed at all the cancers associated with hpv and in most cases there is high suspicion that the integration of the hpv dna is causal to the cancer.
a few leading docs do understand the association with so much disease, but the knowledge is not widespread, this leads me to believe that hpv testing may have a future beyond the cervix tom
My understanding is the Sequenom collaboration was to develop pre-natal diagnostic tests.The goal is to become the gold standard in providing solutions to tests for conditions such as Cystic Fibrosis,Down Syndrome,and Tay-Sachs by non-invasive diagnostics.The strategic collaboration began in January 07'.Digene had entered into a licensing agreement for CF which was to be filed with the FDA prior to the merger but wasn't.Other overlaps exist between Qgen and Dige which is currently part of the integration process.Hope this is helpful.
Anyway, a healthy QGEN means a growing business for SQNM...Bought some for my folks today QGEN, because this biz of the Genome is bringing some big changes to medicine and huge gains to the shareholders of these companies involved...
I got confused with another company doing the animal stuff for SQNM
Eur J Surg Oncol. 2007 Jun;33(5):569-74. Epub 2007 Feb 22 Evidence for an association of human papillomavirus infection and colorectal cancer.Damin DC, Caetano MB, Rosito MA, Schwartsmann G, Damin AS, Frazzon AP, Ruppenthal RD, Alexandre CO. Division of Coloproctology, Department of Surgery, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. email@example.com
AIM: To investigate the presence of human papillomavirus (HPV) in colorectal carcinomas and the correlation of the viral infection with prognostic factors for the disease outcome. METHODS: Seventy-two patients with primary colorectal adenocarcinoma were studied. From each patient two tissue samples were collected: one sample of the tumor and one sample of normal colorectal tissue from an area located 15 cm away from the tumor. Samples of colorectal mucosa obtained from 30 individuals without malignant disease were also studied as control group. Tissues were initially analyzed through MY/GP nested polymerase chain reaction (PCR) and through GP5+/GP6+ auto-nested PCR. Specific primer sets targeting the E6/E7 region of the HPVs 6, 11, 16, 18, 31, 33, 45 were used for typing. Direct DNA sequencing was conducted to confirm positive PCR results. RESULTS: HPV DNA was detected in colorectal specimens of 60 patients with cancer (83.3%), but in none of the tissues from the non-malignant control group (p<0.001). Twenty-three cancer patients had HPV DNA detected in both the tumor and the matched normal tissue, 23 had HPV only in the tumor, and 14 had HPV only in the normal colorectal tissue. HPV16 was the viral type most frequently detected, being present in 41 out of 60 positive cases (68.3%). No correlation between the presence of the virus and specific prognostic predictors for the disease outcome was observed. CONCLUSION: HPV is present in the colon and rectum of most patients with colorectal adenocarcinoma, suggesting that this virus may be related to the pathogenesis of colorectal cancer.